摘要
目的探讨人参皂苷Rh2联合顺铂^(+)培美曲塞化疗治疗晚期肺癌的疗效及对患者肿瘤标志物及免疫功能的影响。方法根据治疗方式的不同将106例肺癌患者分为对照组和观察组,每组53例,对照组患者给予顺铂^(+)培美曲塞化疗,观察组患者给予顺铂^(+)培美曲塞化疗联合人参皂苷Rh2治疗。比较两组患者的临床疗效、血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)]水平、免疫功能指标(CD3^(+)、CD4^(+)、CD8^(+),计算CD4^(+)/CD8^(+))及不良反应发生情况。结果观察组患者的治疗总有效率明显高于对照组患者,差异有统计学意义(P﹤0.01)。治疗后,两组患者血清CEA、CA125、CYFRA21-1水平均低于本组治疗前,且观察组患者血清CEA、CA125、CYFRA21-1水平均低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者CD3^(+)、CD4^(+)水平和CD4^(+)/CD8^(+)均低于本组治疗前,CD8^(+)水平均高于本组治疗前,且观察组患者CD3^(+)、CD4^(+)水平和CD4^(+)/CD8^(+)均高于对照组,CD8^(+)水平低于对照组,差异均有统计学意义(P﹤0.05)。观察组患者血小板减少、白细胞减少发生率均明显低于对照组,差异均有统计学意义(P﹤0.01)。结论人参皂苷Rh2联合化疗可明显提高肺癌的疗效,减少化疗对机体免疫功能的损伤,降低肿瘤标志物水平和不良反应发生率。
Objective To investigate the effect of ginsenoside Rh2 combined with cisplatin^(+)pemetrexed in the treatment of advanced lung cancer and its influence on tumor markers and immune function of patients.Method A total of106 lung cancer patients were divided into control group and observation group according to different treatment methods,with 53 cases in each group.The control group were given cisplatin^(+)pemetrexed chemotherapy,and the observation group were given cisplatin^(+)pemetrexed chemotherapy combined with ginsenoside Rh2.The clinical efficacy,serum tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),cyto-keratin 19 fragment antigen 21-1(CYFRA21-1)]levels,immune function indicators(CD3^(+),CD4^(+),CD8^(+),calculate CD4^(+)/CD8^(+))and occurrence of adverse events were compared between the two groups.Result The total effective rate of treatment in the observation group was significantly higher than that in the control group,and the difference was statistically significant(P<0.01).After the treatment,the levels of serum CEA,CA125,and CYFRA21-1 in the two groups were lower than those before the treatment,and the serum levels of CEA,CA125,and CYFRA21-1 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)in the two groups were lower than those before the treatment,and the levels of CD8^(+)were higher than before the treatment,the levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,and the level of CD8^(+)in the observation group was lower than that in the control group,and the differences were statistically significant(P<0.05).The incidences of thrombocytopenia and leukopenia in the observation group were significantly lower than those in the control group,and the differences were statistically significant(P<0.01).Conclusion Ginsenoside Rh2 combined with chemotherapy can significantly
作者
赵明燕
胡述博
楚旭
秋玉珍
ZHAO Mingyan;HU Shubo;CHU Xu;QIU Yuzhen(Department of Oncology,Zhumadian Central Hospital,Zhumadian 463000,He’nan,China)
出处
《癌症进展》
2022年第24期2553-2556,共4页
Oncology Progress
关键词
肺癌
人参皂苷RH2
化疗
临床疗效
lung cancer
ginsenoside Rh2
chemotherapy
clinical efficacy
